This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Beta thalassaemia trait (carrier)

Authoring team

Thalassaemia minor refers to individuals who are heterozygous for the thalassaemic gene (i.e. beta thalassaemia carriers), either:

  • heterozygous for beta+ - ie. beta+/beta; or
  • heterozygous for beta0 - ie beta0/beta

The carrier incidence of beta thalassaemia in the UK amongst Asian communities is (1):

  • 1 in 7 to 1 in 10 for Gujeratis
  • 1 in 10 for Sindis
  • 1 in 20 for South Indians
  • 1 in 25 for Pakistanis
  • 1 in 15 to 1 in 30 for Punjabis and Bangladeshis

In people from areas of the world without malaria the incidence is much lower e.g. 1 in 1000 English caucasians are beta thalassaemia carriers.

Affected individuals are usually asymptomatic and anaemia, when present, is mild. Thalassaemia trait is believed to offer resistance against falciparum malaria, accounting for it's prevalence in those parts of the world where malaria is endemic.

The red cells are hypochromic and microcytic and there is a low MCV and MCH. Confusion with iron deficiency anaemia is avoided as:

  • serum iron and serum ferritin are normal and serum electrophoresis shows a raised Hb-A2 and usually a raised Hb-F
  • the red blood cell count is increased; in iron deficiency it is low
  • iron supplements are of no benefit in thalassaemia minor

Recognition of beta-thalassaemia trait is important as it permits subsequent genetic counselling.

Reference:

  1. British Journal of Haematology (1991), 78, 242-7.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.